Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/45360
Título
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
Autor
Año del Documento
2017
Editorial
Oxford University Press
Descripción
Producción Científica
Documento Fuente
Journal of Antimicrobial Chemotherapy,2017, vol. 72, n. 7, p. 2083-2088
Resumo
Background: A broader extent of amino acid substitutions in the integrase of HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir in HIV-2 infection. Few studies have examined the virological response to dolutegravir in HIV-2 patients that failed raltegravir.
Methods: All patients recorded in the HIV-2 Spanish cohort were examined. The integrase coding region was sequenced in viraemic patients. Changes associated with resistance to raltegravir and dolutegravir in HIV-1 were recorded.
Results: From 319 HIV-2-infected patients recorded in the HIV-2 Spanish cohort, 53 integrase sequences from 30 individuals were obtained (20 raltegravir naive and 10 raltegravir experienced). Only one secondary mutation (E138A) was found in one of the 20 raltegravir-naive HIV-2 patients. For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one). Of note, all patients with Y143G and N155H developed a rare non-polymorphic mutation at codon 153. Rescue therapy with dolutegravir was given to 5 of these 10 patients. After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound. In two of them N155H was replaced by Q148K/R and in another by G118R.
Conclusions: A wide repertoire of resistance mutations in the integrase gene occur in HIV-2-infected patients failing on raltegravir. Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
Materias Unesco
32 Ciencias Médicas
Palabras Clave
VIH
Mutación
Raltegravir
Dolutegravir
ISSN
0305-7453
Revisión por pares
SI
Patrocinador
Fondo de Investigación Sanitaria-Fondos FEDER (FIS, PI13/01574; ICI14/0274, CES12/003, FI14/00264, CD14/00243)
Version del Editor
Propietario de los Derechos
© Oxford University Press
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Arquivos deste item
![Attribution-NonCommercial-NoDerivatives 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by-nc-nd.png)